Ask about this productRelated genes to: Bcat1 antibody
- Gene:
- BCAT1 NIH gene
- Name:
- branched chain amino acid transaminase 1
- Previous symbol:
- BCT1
- Synonyms:
- -
- Chromosome:
- 12p12.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-03-07
Related products to: Bcat1 antibody
Related articles to: Bcat1 antibody
- Esophagogastric adenocarcinomas have poor survival, and accurate prognosis assessment is required to guide appropriate treatment. Pre-treatment planning can be challenging and would benefit from non-invasive prognostic tools. Methylated circulating tumor DNA (ctDNA) has prognostic value in colorectal cancer. The aim of the study was to evaluate the prognostic value of methylated ctDNA biomarkers in esophageal and gastric cancers. Circulating cell free DNA, isolated from plasma collected prior to treatment from 122 patients diagnosed with esophagogastric cancer was assayed for methylated BCAT1 and IKZF1. Test positivity was assessed against clinicopathological features, and prognostic factors associated with recurrence-free survival (RFS) and overall survival (OS) were investigated with Cox regression analysis. Methylated BCAT1/IKZF1 DNA was detected in 54.9% (67/122) of patients following a diagnosis of esophagogastric cancer. Advanced disease had higher detection rates, with a significant association between test positivity and pathological node-positive disease (odds ratio [OR] for pN2: 5.63, 95% CI 1.27-24.86, P = 0.02), and metastatic disease (OR 4.92, 95% CI 1.94-12.47, P < 0.01). A positive ctDNA result at diagnosis was associated with worse RFS for individuals considered in remission (hazard ratio [HR] 4.49, 95% CI 1.48-13.67, P < 0.01), and a worse OS in all patients (HR 3.64, 95% CI 1.73-7.68, P < 0.01), independent of stage and other clinical variables, compared to a negative ctDNA result. Detection of circulating methylated BCAT1/IKZF1 DNA is a promising prognostic biomarker in esophagogastric cancers. Prospective studies are warranted to investigate the utility of methylated BCAT1/IKZF1 for monitoring treatment response and for risk stratification to guide adjuvant therapeutic decisions. - Source: PubMed
Chan Mei MeiRoy Amitesh CWatson David IBright TimSheehan-Hennessy LorraineYoung Graeme PHussey DamianPedersen Susanne KWinter Jean MSymonds Erin L - The heterogeneous and immunosuppressive tumor microenvironment (TME) in hepatocellular carcinoma (HCC) contributes to poor immunotherapy responses. Tumor-associated macrophages (TAM) are central to the immunosuppressive TME, but how metabolic programs regulate TAM pro-tumorigenic functions remain incompletely understood. Here, we identify branched-chain amino acid transaminase 1 (BCAT1) as a metabolic checkpoint in TAMs constraining tumor progression. Compared with wild-type TAMs, BCAT1-deficient TAMs have increased intracellular crotonate, as well as enhanced histone H3 lysine 14 crotonylation, upregulated lipid metabolism genes and an immunosuppressive phenotype. In HCC mouse models, BCAT1-deficient TAMs aggravate tumor burden and suppress CD8 T cell-mediated antitumor immunity, while myeloid-specific BCAT1 overexpression or adoptive transfer of BCAT1 macrophages stimulates the antitumor immune response and improves anti-PD1 therapy responses. In summary, our data support a BCAT1-mediated regulation of crotonate-dependent epigenetic modulation of immunosuppressive TAMs in HCC, and indicate BCAT1 macrophages as an adjuvant treatment for enhancing immune checkpoint blockade therapy. - Source: PubMed
Publication date: 2026/05/11
Zhang WeizhiLiang ShuhangHan SitaoZha QingruiSun LinmaoTao ShengweiZhang YunguangChu JunhuiChu QiZhang NingMa KunLiu YufengCui TianmingGu XuetianCheng ChengGuo XinyuFu YuminXing ChangjianDuan JiaweiLong YanYang DongdongWang JiabeiLiu Lianxin - Cytosolic branched-chain aminotransferase 1 (BCAT1) is a canonical transaminase that catalyses the breakdown of essential amino acids, including leucine, isoleucine and valine. Our previous work showed that BCAT1 also contains a redox-active CXXC motif with antioxidant activity, reducing intracellular reactive oxygen species (ROS) in the monocytic U937 cell line. Moreover, these cells display decreased expression of CD14/CD68 compared to controls, a phenotype indicative of M2 macrophage polarisation. Given that Extracellular Vesicle (EV) release is associated with oxidative stress, and that there is increasing interest in the therapeutic use of M1-and M2-derived macrophage EVs, we investigated whether the BCAT1 CXXC motif could modulate EV release in U937 cells constitutively overexpressing WT BCAT1, a CXXC motif mutant (CXXS BCAT1), or vector control. Here, we show that whilst WT BCAT1 cells display significantly lower intracellular ROS compared to controls, nanoparticle tracking analysis demonstrates that WT BCAT1 significantly increases EV generation compared to CXXS BCAT1 and vector controls under both normal (10% FBS) and serum-starved (0% FBS) conditions. Analysis of CD63/CD81/CD9 tetraspanin composition revealed that the majority of EVs produced were CD63, with serum starvation further increasing CD63 EV abundance. Taken together, these data indicate that BCAT1, and its redox-active CXXC motif, may play a novel role in EV biogenesis in macrophage-like cells. - Source: PubMed
Publication date: 2026/05/09
Hillier JamesBrunet Mathieu YTerry RebeccaWhittaker JoanneAllcot GemmaCox Sophie CEsteban PatriciaColes Steven JWall Ivan - Pancreatic adenocarcinoma (PAAD) is characterized by profound metabolic reprogramming, including altered branched-chain amino acid (BCAA) metabolism. While the tumor-promoting role of branched-chain aminotransferase 2 (BCAT2) in PAAD has been well documented, the function of branched-chain aminotransferase 1 (BCAT1) remains unclear, particularly in PAAD cells with low endogenous BCAT1 expression. This study aimed to define the context-dependent role of BCAT1 in PAAD and to elucidate the underlying molecular mechanisms. - Source: PubMed
Publication date: 2026/05/07
Huang HuiminLiu XinhengChen XiTang XinyiQiu HanxiangYu HuajunJin GuihuaLan Linhua - Hypoxia is a common characteristic of solid tumors, especially in hepatocellular carcinoma (HCC). Hypoxia-inducible factors (HIFs), particularly HIF-1α, mediate metabolic adaptation, which is crucial for survival of hypoxic cells. Branched-chain amino transferase 1 (BCAT1) catalyzes the reversible transamination reaction between branched-chain amino acids (BCAAs) and branched-chain keto acids (BCKAs), involving the inter-conversion of α-ketoglutarate (α-KG) and glutamate. We investigate and delineate the mechanisms by which BCAT1 consumes α-KG and stabilizes HIF-1α, suppressing α-KG-dependent oxygen dehydrogenase, prolyl hydroxylase-domain protein (PHD), inducing HIF-1α-mediated metabolic reprogramming and promoting hypoxic survival of HCC. We evaluate the potency of a BCAT1 inhibitor, ERG245, as a single or combination treatment with tyrosine kinase inhibitor (TKI) in vivo. We further validate the over-expression and correlation of BCAT1 and HIF-1α downstream metabolic genes in HCC clinical samples. Our results indicate that BCAT1 benefits HCC growth through HIF-1α-induced metabolic reprogramming. Targeting BCAT1 will provide an effective therapeutic strategy for HCC patients. - Source: PubMed
Publication date: 2026/04/29
Zhang Misty ShuoKwan Kenneth Kin-LeungTse Aki Pui-WahWang GengchaoWei Larry LaiSun KejieChui Noreen Nog-QinLee DerekBao Macus Hao-RanPang XiaoxuanWu ZhenqiChen YanyanWang YangyangYang ZifanJiang XueLi QidongZhang YanZhong YajieCheu Jacinth Wing-SumChen YilingLi WeixingWong Chun-MingWang JianingCai ZongweiZhang QiLiang TingboNg Irene Oi-LinPapathanassiu Adonia EWong Carmen Chak-Lui